Share

EORTC-1333-GUCG/PEACE III Trial Statement

EORTC is pleased to announce that the phase III EORTC-1333-GUCG/PEACE III trial database is locked. It reached data maturity for its primary endpoint (radiological progression free survival) and analysis has started. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities.

The phase III EORTC-1333-GUCG/PEACE III trial is a randomised multicentre phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

This trial is supported by an investigator driven clinical trial agreement from Bayer HealthCare Pharmaceuticals and Astellas Pharma Europe.

ENDS

Back to news list

Related News

  • First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma

  • New results and forthcoming trials presented at ESMO 2025 underline EORTC’s commitment to patient-centred research

  • First Site Activated in EU-Funded DE-ESCALATE Clinical Trial on Advanced Metastatic Prostate Cancer

  • EORTC in the spotlight at ASCO 2025

  • EORTC’s presence at ASCO 2025

  • New study confirms link between cancer patients’ quality of life and survival

  • New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024

  • Late Breaking Results from the EORTC 1333/PEACE III phase III trial

  • EORTC-1333-GUCG/PEACE III trial endpoint reached

  • Completion of Patient Recruitment for International TIGER Study